In the phase 2 NICHE-3 trial, patients with locally advanced mismatch repair-deficient colon cancer who were treated with neoadjuvant anti-PD1 and anti-LAG3 agents showed high rates of ...

OXY trades at ~$51, with a target of $60, reflecting an 18% upside, anchored by Fibonacci resistance levels. An RSI of 27.46 signals oversold conditions, potentially undervaluing OXY; no immediate ...

In this article, we are going to take a look at where Occidental Petroleum Corporation (NYSE:OXY) stands against the other not-tech AI stocks. Investors have been desperately searching for a safer ...

OXY's Q2 results beat expectations, with EPS of $1.03 and revenue of $6.88 billion, leading to several Wall Street upgrades. Risks include falling oil prices, a strong dollar, rising labor costs ...

In this article, we are going to take a look at where Occidental Petroleum Corporation (NYSE:OXY) stands against the other beaten down stocks. The equity market is on the cusp of a significant ...

The $55 billion Anadarko deal was a huge undertaking for Oxy, which itself had an enterprise value of about $50 billion at the time. The cash portion was partly financed with a $10 billion ...